Xenobiotic immunosuppressive agents: Therapeutic effects in animal models of autoimmune diseases

Rheumatology International

Volumn 17, Issue 3, 1997, Pages 85-90

  Burkhardt, H ^a   Kalden, J R ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Animal models; Autoimmune disease; Immunosuppressive drugs

Indexed keywords

15 DEOXYSPERGUALIN; BREQUINAR; CYCLOSPORIN; HEAT SHOCK PROTEIN 70; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; XENOBIOTIC AGENT;

ANIMAL MODEL; AUTOIMMUNITY; DIABETES MELLITUS; DRUG THERAPY; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THYROIDITIS; UVEORETINITIS;

ANIMALS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; HAPLORHINI; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; RATS; XENOBIOTICS;

EID: 0030689753     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002960050014     Document Type: Review

References (58)

1. Sigal NH, Dumont FJ (1992) Cyclosporin A, FK-506 and rapamycin: pharmacologic probes of lymphocyte signal transduction. Annu Rev Immunol 10: 519-560
2. Brazelton TR, Morris RE (1996) Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Curr Opin Immunol 8: 710-720
3. Terada N, Takase K, Papst P, Nairn AC, Gelfand EW (1995) Rapamycin inhibits ribosomal protein synthesis and induces G1 prolongation in mitogen-activated T lymphocytes. J Immunol 155: 3418-3426
4. Feuerstein N, Huang D, Prystowsky MB (1995) Rapamycin selectively blocks interleukin-2-induced proliferating cell nuclear antigen gene expression in T lymphocyte. Evidence for inhibition of CREB/ATF binding activities. J Biol Chem 270: 9454-9458
5. Schuller-Levis GB, Kozlowski PB, Wisniewski HM (1986) Cyclosporin A treatment of an induced attack in a chronic relapsing model of experimental allergic encephalomyelitis. Clin Immunol Immunopathol 40: 244-252
6. Mori Y, Suko M, Okudaira H, Matsuba I, Tsuruoka A, Sasaki A, Yokoyama H, Tanase T, Shida T, Nishimura M (1986) Preventive effects of cyclosporin on diabetes in NOD mice. Diabetologia 29: 244-247
7. Drachman DB, Adams RN, McIntosh K, Pestronk A (1985) Treatment of experimental myasthenia gravis with cyclosporin A. Clin Immunol Immunopathol 34: 174-188
8. McIntosh KR, Drachman DB (1986) Induction of suppressor cells specific for AChR in experimental autoimmune myasthenia gravis. Science 232: 401-403
9. Gunn HC, Ryffel B (1986) Successful treatment of autoimmunity in (NZB×NZW)F1 mice with cyclosporin and (Nva2)-cyclosporin: II. Reduction of glomerulonephritis. Clin Exp Immunol 64: 234-242
10. Berden JH, Faaber P, Assmann KJ, Rijke TP (1986) Effects of cyclosporin A on autoimmune disease in MRL/1 and BXSB mice. Scand J Immunol 24: 405-411
11. Mountz JD, Smith HR, Wilder RL, Reeves JP, Steinberg AD (1987) CS-A therapy in MRL-lpr/lpr mice: amelioration of immunopathology despite autoantibody production. J Immunol 138: 157-163
12. Jabs DA, Lee B, Burek CL, Saboori AM, Prendergast RA (1996) Cyclosporine therapy suppresses ocular and lacrimal gland disease in MRL/Mp-lpr/lpr mice. Invest Ophthalmol Vis Sci 37: 377-383
13. Takagishi K, Kaibara N, Hotokebuchi T, Arita C, Morinaga M, Arai K (1986) Effects of cyclosporin on collagen induced arthritis in mice. Ann Rheum Dis 45: 339-344
14. Bakker NP, Van Besouw N, Groenestein R, Jonker M, 't Hart LA (1993) The anti-arthritic and immunosuppressive effects of cyclosporin A on collagen-induced arthritis in the rhesus monkey. Clin Exp Immunol 93: 318-322
15. Kaibara N, Hotokebuchi T, Takagishi K, Katsuki I (1983) Paradoxical effects of cyclosporin A on collagen arthritis in rats. J Exp Med 158: 2007-2015
16. Polman CH, Matthaei I, de Groot CJ, Koetsier JC, Sminia T, Dijkstra CD (1988). Low-dose cyclosporin A induces relapsing remitting experimental allergic encephalomyelitis in the Lewis rat. J Neuroimmunol 17: 209-216
17. Feurer C, Chow LH, Borel JF (1988) Preventive and therapeutic effects of cyclosporin and valine 2-dihydro-cyclosporin in chronic relapsing experimental allergic encephalomyelitis in the Lewis rat. Immunology 63: 219-223
18. Prud'homme GJ, Parfrey NA, Vanier LE (1991) Cyclosporine-induced autoimmunity and immune hyperreactivity. Autoimmunity 9: 345-356
19. Damoiseaux JG, Beijleveld LJ, van Breda Vriesman PJ (1997) Multiple effects of cyclosporin A on the thymus in relation to T-cell development and autoimmunity. Clin Immunol Immunopathol 82: 197-202
20. Kai N, Motojima K, Tsunoda T, Kanematsu T (1993) Prevention of insulitis and diabetes in nonobese diabetic mice by administration of FK506. Transplantation 55: 936-940
21. Takabayashi K, Koike T, Kurasawa K, Matsumura R, Sato T, Tomioka H, Ito I, Yoshiki T, Yoshida S (1989) Effect of FK-506, a novel immunosuppressive drug on murine systemic lupus erythematosus. Clin Immunol Immunopathol 51: 110-117
22. Entani C, Izumino K, Iida H, Fujita M, Asaka M, Takata M, Sasayama S (1993) Effect of a novel immunosuppressant. FK506, on spontaneous lupus nephritis in MRL/MpJ-lpr/lpr mice. Nephron 64: 471-475
23. Furukawa F, Imamura S, Takigawa M (1995) FK506: therapeutic effects on lupus dermatoses in autoimmune-prone MRL/Mp-lpr/lpr mice. Arch Dermatol Res 287: 558-563
24. Yamamoto K, Mori A, Nakahama T, Ito M, Okudaira H, Miyamoto T (1990) Experimental treatment of autoimmune MRL-lpr/lpr mice with immunosuppressive compound FK506. Immunology 69: 222-227
25. Inamura N, Hashimoto M, Nakahara K, Aoki H, Yamaguchi I, Kohsaka M (1988) Immunosuppressive effects of FK506 on collagen-induced arthritis in rats. Clin Immunol Immunopathol 46: 82-90
26. Arita C, Hotokebuchi T, Miyahara H, Arai K, Sugioka Y, Kaibara N (1990) Inhibition by FK506 of established lesions of collagen-induced arthritis in rats. Clin Exp Immunol 82: 456-461
27. Kawashima H, Fujino Y, Mochizuki M (1988) Effects of a new immunosuppressive agent, FK506, on experimental autoimmune uveoretinitis in rats. Invest Ophthalmol Vis Sci 29: 1265-1271
28. Carlson RP, Hartman DA, Tomchek LA, Walter TL, Lugay JR, Calhoun W, Sehgal SN, Chang JY (1993) Rapamycin, a potential disease-modifying antiarthritic drug. J Pharmacol Exp Ther 266: 1125-1138
29. Baeder WL, Sredy J, Sehgal SN, Chang JY, Adams LM (1992) Rapamycin prevents the onset of insulin-dependent diabetes mellitus (IDDM) in NOD mice. Clin Exp Immunol 89: 174-178
30. Warner LM, Adams LM, Sehgal SN (1994) Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus. Arthritis Rheum 37: 289-297
31. Morris RE (1996) Mechanisms of action of new immunosuppressive drugs. Kidney Int [Suppl] 53: S26-S38
32. Ransom JT (1995) Mechanism of action of mycophenolate mofetil. Ther Drug Monit 17: 681-684
33. Allison AC, Eugui EM (1994) Preferential suppression of lymphocyte proliferation by mycophenolic acid and predicted long-term effects of mycophenolate mofetil in transplantation. Transplant Proc 26: 3205-3210
34. Laurent AF, Dumont S, Poindron P, Müller CD (1996) Mycophenolic acid suppresses protein N-linked glycosylation in human monocytes and their adhesion to endothelial cells and to some substrates. Exp Hematol 24: 59-67
35. Mizuno K, Masatoshi T, Takada M, Hayashi M, Atsumi K, Asano K, Matsuda T (1974) Studies on bredinin. I: Isolation; characterization and biological properties. J Antibiot 27: 775-782
36. Sakagushi K, Tsujino M, Yoshizawa M, Mizuno K, Hayano K (1975) Action of bredinin on mammalian cells. Cancer Res 35: 1643-1648
37. Hirohata S, Yanagida T (1995) Inhibition of expression of cyclin A in human B cells by an immunosuppressant mizoribine. J Immunol 155: 5175-5183
38. Kamada H, Nakagami K (1996) Effect of mizoribine on collagen-induced arthritis in mice. Jpn J Pharmacol 70: 169-175
39. Soga T, Ishigatsubo Y, Kitamura H, Okubo T (1996) Effect of mizoribine on pulmonary lesions in MRL/lpr/lpr mice. Autoimmunity 25: 9-18
40. Siemasko KF, Chong AS, Williams JW, Bremer EG, Finnegan A (1996) Regulation of B cell function by the immunosuppressive agent leflunomide. Transplantation 61: 635-642
41. Morris RE, Huang X, Cao W, Zheng B, Shorthouse RA (1995) Leflunomide (HWA 486) and its analog suppress T- and B-cell proliferation in vitro, acute rejection, ongoing rejection, and antidonor antibody synthesis in mouse, rat, and cynomolgus monkey transplant recipients as well as arterial intimal thickening after balloon catheter injury. Transplant Proc 27: 445-447
42. Cao WW, Kao PN, Aoki Y, Xu JC, Shorthouse RA, Morris RE (1996) A novel mechanism of action of the immunomodulatory drug, leflunomide: augmentation of the immunosuppressive cytokine, TGF-beta 1, and suppression of the immunostimulatory cytokine, IL-2. Transplant Proc 28: 3079-3080
43. Davis JP, Cain GA, Pitts WJ, Magolda RL, Copeland RA (1996) The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry 35: 1270-1273
44. Fairbanks LD, Bofill M, Ruckemann K, Simmonds HA (1995) Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors. J Biol Chem 270: 29682-29689
45. Steele DM, Hullet DA, Bechstein WO, Kowalski J, Smith LS, Kennedy E, Allison AC, Sollinger HW (1993) Effects of immunosuppressive therapy on the rat aortic allograft model. Transplant Proc 25: 754-755
46. O' Neill JK, Baker D, Davison AN, Waggon KK, Jaffee BD, Turk JL (1992) Therapy of chronic relapsing experimental allergic encephalomyelitis and the role of the blood-brain barrier: elucidation by the action of Brequinar sodium. J Neuroimunol 38: 53-62
47. Bartlett RR, Anagnostopulos H, Zielinski T, Mattar T, Schleyerbach R (1993) Effects of leflunomide on immune responses and models of inflammation. Springer Semin Immunopathol 14: 381-394
48. Thoss K, Henzgen S, Petrow PK, Katenkamp D, Bräuer R (1996) Immunomodulation of rat antigen-induced arthritis by leflunomide alone and in combination with cyclosporin A. Inflamm Res 45: 103-107
49. Robertson SM, Lang LS (1994) Leflunomide: inhibition of S-antigen induced autoimmune uveitis in Lewis rats. Agents Actions 42: 167-172
50. Maeda K, Umeda Y, Saino T (1993) Synthesis and background chemistry of 15-deoxyspergualin. Ann NY Acad Sci 685: 123-135
51. Nadler SG, Tepper MA, Schacter B, Mazzucco CE (1992) Interaction of the immunosuppressant deoxyspergualin with a member of the Hsp70 family of heat shock proteins. Science 258: 484-486
52. Tepper MA, Nadler SG, Esselstyn JM, Sterbenz KG (1995) Deoxyspergualin inhibits kappa light chain expression in 70Z/3 pre-B cells by blocking lipopolysaccharide-induced NF-kappa B activation. J Immunol 155: 2427-2436
53. Wang B, Benoist C, Mathis D (1996) The immunosuppressant 15-deoxyspergualin (correction of 1,5-deoxyspergualin) reveals commonality between preT and preB cell differentiation. J Exp Med 183: 2427-2436
54. Nikolic-Paterson DJ, Kerr PG, Lan HY, Tesch GH, Atkins RC (1995) Deoxyspergualin: a new immunosuppressive drug for the treatment of autoimmune disease (editorial). Nephron 70: 391-396
55. Martin DF, DeBarge LR, Nussenblatt RB, Chan CC, Roberge FG (1995) Synergistic effect of rapamycin and cyclosporin A in the treatment of experimental autoimmune uveoretinitis. J Immunol 154: 922-927
56. Lemire JM (1992) Immunomodulatory role of 1,25-dihydroxy-vitamin D3. J Cell Biochem 49: 26-31
57. Branisteanu DD, Waer M, Sobis H, Marcelis S, Vandeputte M, Bouillon R (1995) Prevention of murine experimental allergic encephalomyelitis: cooperative effects of cyclosporine and I alpha, 25-(OH)2D3. J Neuroimmunol 61: 151-160
58. Fournier C, Gepner P, Sadouk M, Charreire J (1990) In vivo beneficial effects of cyclosporin A and 1,25-dihydroxyvitamin D3 on the induction of experimental autoimmune thyroiditis. Clin Immunol Immunopathol 54: 53-63